title: Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.
authors.forename: Adele L
authors.initials: AL
authors.lastname: McCormick
authors.forename: Ruth L
authors.initials: RL
authors.lastname: Goodall
authors.forename: Aengus
authors.initials: A
authors.lastname: Joyce
authors.forename: Nicaise
authors.initials: N
authors.lastname: Ndembi
authors.forename: Mike
authors.initials: M
authors.lastname: Chirara
authors.forename: Pauline
authors.initials: P
authors.lastname: Katundu
authors.forename: Sarah
authors.initials: S
authors.lastname: Walker
authors.forename: David
authors.initials: D
authors.lastname: Yirrell
authors.forename: Charlie F
authors.initials: CF
authors.lastname: Gilks
authors.forename: Deenan
authors.initials: D
authors.lastname: Pillay
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004338:Drug Combinations; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D009154:Mutation / Q000187:drug effects / Q000235:genetics; D019562:Viral Load / Q000187:drug effects; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; C109078:lamivudine, zidovudine drug combination; D019259:Lamivudine; D015215:Zidovudine